AiCure

Archives

Choose a date range

From To

Choose one or more categories

Categories:



Show only original CenterWatch stories

 


Report: Pharma is improving medicines access, but progress is uneven

Monday, November 17, 2014 02:30 PM

The world’s leading pharmaceutical companies are doing more to improve access to medicine in developing countries, with a raft of new initiatives, scale-ups and innovations over the last two years. However, the industry struggles to perform well in some practices that matter, according to the 2014 Access to Medicine Index, published by the Access to Medicine Foundation, a nonprofit organization based in the Netherlands that aims to advance access to medicine by encouraging the pharmaceutical industry to play a greater role in improving access to medicine in less developed countries.

More... »


Merck, Pfizer ink alliance on anti-PD-L1

Monday, November 17, 2014 02:28 PM

Merck has entered into a global agreement with Pfizer to co-develop and co-commercialize MSB0010718C, an investigational anti-PD-L1 antibody currently in development by Merck as a potential treatment for multiple tumor types to accelerate the two companies’ presence in immuno-oncology.

More... »


Bone Therapeutics, Kasios collaborate on optimization of spinal fusion procedures

Monday, November 17, 2014 02:27 PM

Bone Therapeutics, a Belgium regenerative therapy company addressing unmet medical needs releated to bone diseases and orthopaedics, and Kasios, a French synthetic bone substitute specialist, have announce a two-year collaboration to develop a novel product for spinal fusion procedures. The collaboration combines Bone Therapeutics' allogeneic osteoblastic cell therapy product ALLOB with Kasios's synthetic micro-granules bone substitute. The project is subsidized by the government of the Walloon Region.

More... »

Actavis to acquire Allergan for $66 billion

Monday, November 17, 2014 02:22 PM

Dublin-based Actavis, a global, integrated, specialty pharmaceutical company has announced it will acquire Allergan, a multi-specialty healthcare company based in Irvine, Calif., for approximately $66 billion, or $219 per share.

More... »

Clinical trials not yet paperless

Monday, November 17, 2014 08:00 AM

Typically, when a major shift occurs in how things are managed, there is an adjustment period during which users embrace the new change but are reluctant to let go of some long-standing parts of the old way. 

More... »

Recipharm acquires Lusomedicamenta

Friday, November 14, 2014 02:21 PM

Recipharm, a Swedish pharmaceutical contract development and manufacturing organization (CDMO), has acquired Lisbon, Portugal-based CDMO Lusomedicamenta Sociedade Técnica Farmacêutica.

More... »

Catalent acquires Micron Technologies

Friday, November 14, 2014 02:19 PM

Catalent, a global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, has acquired Micron Technologies, a Boise, Idaho-based global provider of particle size engineering technologies.

More... »

Report: over 6,000 trials conducted in North Carolina since 1999

Friday, November 14, 2014 02:15 PM

Working with institutions in Research Triangle Park and throughout North Carolina, U.S. biopharmaceutical research companies have conducted over 6,000 clinical trials of new medicines in the state since 1999, according to a new report by the Pharmaceutical Research and Manufacturers of America (PhRMA).

More... »

CISCRP, ACRP collaborate on 5K to recognize clinical trial volunteers

Friday, November 14, 2014 10:54 AM

The Center for Information and Study on Clinical Research Participation (CISCRP) and the Association for Clinical Research Professionals (ACRP), two independent, nonprofit organizations based Boston, Mass. and Alexandria, Va., respectively, have announced the upcoming Medical Heroes Appreciation 5K Run & Walk in Salt Lake City, Utah, to celebrate those who volunteer to participate in clinical research and raise awareness about the importance of clinical research in advancing public health.

More... »

Precision Therapeutics changes name to Helomics, reorganizes management

Friday, November 14, 2014 10:51 AM

Precision Therapeutics has changed its name to Helomics, a Pittsburgh, Pa.-based, privately held comprehensive personalized healthcare company that develops next-generation diagnostics for the oncology field.

More... »

CenterWatch Drugs in Clinical Trials
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

November 24

Tufts CSDD’s $2.6 billion price tag to develop and bring a new drug to market raises questions, criticisms

Medidata joins GlaxoSmithKline in study to evaluate the impact of wearing mobile devices in clinical trials

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

October

CROs driving changes in patient recruitment
Data- and tech-aided enrollment services a competitive advantage

Trials with in-home nurses poised to grow
Higher expense, but may improve recruitment and retention for select trials

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs